RxDoctor Payments Data

Andrew Chesson, MD

Family Medicine · Maiden, NCNPI 1871519066

Payments from drug & device makers

$434in general payments, 2019–2025

Across 26 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$284
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$41
  • AbbVie$28
  • Lilly USA, LLC$18
  • Merck$16
  • GSK$16
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$434100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$434 in reported general payments places this provider in the 55th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,992
Medicare patients
58
Services billed
187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide111$109,420
EliquisApixaban94$76,126
JardianceEmpagliflozin93$65,094
XareltoRivaroxaban44$32,848
EntrestoSacubitril/Valsartan17$16,902
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$12,653
JanuviaSitagliptin Phosphate12$11,232
Breo ElliptaFluticasone/Vilanterol21$10,708
Spiriva HandihalerTiotropium Bromide18$10,260
Victoza 3-PakLiraglutide11$7,976
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$7,522
Incruse ElliptaUmeclidinium Bromide14$5,610
Atorvastatin Calcium411$3,273
Novolog Mix 70-30Insulin Aspart Prot/Insuln Asp12$3,268
Omeprazole194$2,415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog Mix 70-30$284$112,688123 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$16$28,97056 claims
MerckJanuvia$16$11,23212 claims
AbbVieSynthroid$28$1,46423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Maiden

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →